Previous close | 18.86 |
Open | 18.90 |
Bid | 18.38 x 0 |
Ask | 19.32 x 0 |
Day's range | 18.62 - 18.92 |
52-week range | 14.81 - 37.29 |
Volume | |
Avg. volume | 203,476 |
Market cap | 3.347B |
Beta (5Y monthly) | 0.96 |
PE ratio (TTM) | 471.25 |
EPS (TTM) | 0.04 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec announces agreement with Janssen to develop immune-based therapies 26.01.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. STRATEGIC PARTNERSHIP LEVERAGES EVOTEC’S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT Hamburg, Germany, 26 January 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a str
To get a sense of who is truly in control of Evotec SE ( ETR:EVT ), it is important to understand the ownership...
Last week saw the newest quarterly earnings release from Evotec SE ( ETR:EVT ), an important milestone in the company's...